Suven Life Sciences Ltd Spends 24% Of Revenue On R&D Pat Up By 55% For The 3rd Quarter Ending Dec 2010

HYDERABAD, INDIA (Jan 31, 2011) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its unaudited financial results for the quarter ended Dec’ 2010. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on Jan 31, 2011 at Hyderabad.

Financial Highlights for the period (9 months) ending Dec ’2010:

Growth in revenue 12.65% (Rs 1052 mil vs. Rs 934 mil)

Growth in PAT 27.27% (Rs 69 mil vs. Rs 54 mil)

Growth in EBIDTA -17.81% (Rs 86 mil vs. Rs105 mil)

R&D cost on revenue 22.31% (Rs 235 million)

During the quarter the company recorded growth in revenue of Rs. 320 mil as compared to Rs. 289 mil for the previous period an increase of 10.71% and recorded growth in profit after tax of Rs. 11.2 mil as compared to Rs. 7.2 mil for the previous period an increase by 55.60%.

Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 78.1 mil (24% on revenue) for the quarter ended Dec’ 2010.

During the quarter there were major qualitative achievements by the grant of 6 product patents to Suven’s drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development targeting conditions such as ADHD, Dementia, Depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia

For more information on Suven please visit our Web site at http://www.suven.com